COVID-19 in immunocompromised children: comparison of SARS-CoV-2 viral load dynamics between the first and third waves

被引:0
作者
Moragas, Matias [1 ]
Golemba, Marcelo D. [1 ]
Fernandez, Maria F. [1 ]
Palladino, Marcela [2 ]
Gomez, Sandra [3 ]
Borgnia, Daniela [1 ]
Ruhle, Martin [1 ]
Arias, Ana [3 ]
Ruvinsky, Silvina [4 ]
Bologna, Rosa [3 ]
Mangano, Andrea [1 ]
机构
[1] Hosp Pediat Prof Dr Juan P Garrahan, Unite Virol & Epidemiol Mol CONICET, Buenos Aires, Argentina
[2] Hosp Pediat Prof Dr Juan P Garrahan, Unite Cuidados Intermedios & Moderados, Buenos Aires, Argentina
[3] Hosp Pediat Prof Dr Juan P Garrahan, Serv Epidemiol & Infectol, Buenos Aires, Argentina
[4] Hosp Pediat Prof Dr Juan P Garrahan, Coordinac Invest, Buenos Aires, Argentina
关键词
COVID-19; Immunocompromised patient; Pediatrics; Population dynamics; Viral load;
D O I
10.1007/s42770-023-01009-y
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
SARS-CoV-2 dynamics across different COVID-19 waves has been unclear in immunocompromised children. We aimed to compare the dynamics of SARS-CoV-2 RNA viral load (VL) during the first and third waves of COVID-19 in immunocompromised children. A retrospective and longitudinal cohort study was conducted in a pediatric referral hospital of Argentina. The study included 28 admitted immunocompromised children with laboratory confirmed SARS-CoV-2 infection. Thirteen acquired the infection during COVID-19 first wave (May to August 2020, group 1 (G1)) and fifteen in the third wave (January to March 2022, group 2 (G2)). RNA viral load measure and its dynamic reconstruction were performed in nasopharyngeal swabs by validated quantitative, real time RT-PCR, and linear mixed-effects model, respectively. Of the 28 children included, 54% were girls, most of them had hemato-oncological pathology (57%), and the median age was 8 years (interquartile range (IQR): 3-13). The dynamic of VL was similar in both groups (P = 0.148), starting from a level of 5.34 log(10) copies/mL (95% confidence interval (CI): 4.47-6.21) in G1 and 5.79 log(10) copies/mL (95% CI: 4.93-6.65) in G2. Then, VL decayed with a rate of 0.059 (95% CI: 0.038-0.080) and 0.088 (95% CI: 0.058-0.118) log(10) copies/mL per day since diagnosis and fell below the limit of quantification at days 51 and 39 after diagnosis in G1 and G2, respectively. Our results evidenced a longer viral RNA persistence in immunocompromised pediatric patients and no difference in VL dynamic between COVID-19 first wave-attributed to ancestral infections-and third wave-attributed to Omicron infections.
引用
收藏
页码:1859 / 1864
页数:6
相关论文
共 32 条
[1]   Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer [J].
Avanzato, Victoria A. ;
Matson, M. Jeremiah ;
Seifert, Stephanie N. ;
Pryce, Rhys ;
Williamson, Brandi N. ;
Anzick, Sarah L. ;
Barbian, Kent ;
Judson, Seth D. ;
Fischer, Elizabeth R. ;
Martens, Craig ;
Bowden, Thomas A. ;
de Wit, Emmie ;
Riedo, Francis X. ;
Munster, Vincent J. .
CELL, 2020, 183 (07) :1901-+
[2]   Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient [J].
Baang, Ji Hoon ;
Smith, Christopher ;
Mirabelli, Carmen ;
Valesano, Andrew L. ;
Manthei, David M. ;
Bachman, Michael A. ;
Wobus, Christiane E. ;
Adams, Michael ;
Washer, Laraine ;
Martin, Emily T. ;
Lauring, Adam S. .
JOURNAL OF INFECTIOUS DISEASES, 2021, 223 (01) :23-27
[3]   Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection [J].
Boucau, Julie ;
Marino, Caitlin ;
Regan, James ;
Uddin, Rockib ;
Choudhary, Manish C. ;
Flynn, James P. ;
Chen, Geoffrey ;
Stuckwisch, Ashley M. ;
Mathews, Josh ;
Liew, May Y. ;
Singh, Arshdeep ;
Lipiner, Taryn ;
Kittilson, Autumn ;
Melberg, Meghan ;
Li, Yijia ;
Gilbert, Rebecca F. ;
Reynolds, Zahra ;
Iyer, Surabhi L. ;
Chamberlin, Grace C. ;
Vyas, Tammy D. ;
Goldberg, Marcia B. ;
Vyas, Jatin M. ;
Li, Jonathan Z. ;
Lemieux, Jacob E. ;
Siedner, Mark J. ;
Barczak, Amy K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (03) :275-277
[4]   Viral Dynamics of Omicron and Delta Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants With Implications for Timing of Release from Isolation: A Longitudinal Cohort Study [J].
Bouton, Tara C. ;
Atarere, Joseph ;
Turcinovic, Jacquelyn ;
Seitz, Scott ;
Sher-Jan, Cole ;
Gilbert, Madison ;
White, Laura ;
Zhou, Zhenwei ;
Hossain, Mohammad M. ;
Overbeck, Victoria ;
Doucette-Stamm, Lynn ;
Platt, Judy ;
Landsberg, Hannah E. ;
Hamer, Davidson H. ;
Klapperich, Catherine ;
Jacobson, Karen R. ;
Connor, John H. .
CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) :E227-E233
[5]   Validation of Laboratory-Developed Molecular Assays for Infectious Diseases [J].
Burd, Eileen M. .
CLINICAL MICROBIOLOGY REVIEWS, 2010, 23 (03) :550-+
[6]   Immunocompromised children and young people are at no increased risk of severe COVID-19 [J].
Chappell, H. ;
Patel, R. ;
Driessens, C. ;
Tarr, A. W. ;
Irving, W. L. ;
Tighe, P. J. ;
Jackson, H. J. ;
Harvey-Cowlishaw, T. ;
Mills, L. ;
Shaunak, M. ;
Gbesemete, D. ;
Leahy, A. ;
Lucas, J. S. ;
Faust, S. N. ;
de Graaf, H. .
JOURNAL OF INFECTION, 2022, 84 (01) :31-39
[7]   Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host [J].
Choi, Bina ;
Choudhary, Manish C. ;
Regan, James ;
Sparks, Jeffrey A. ;
Padera, Robert F. ;
Qiu, Xueting ;
Solomon, Isaac H. ;
Kuo, Hsiao-Hsuan ;
Boucau, Julie ;
Bowman, Kathryn ;
Das Adhikari, U. ;
Winkler, Marisa L. ;
Mueller, Alisa A. ;
Hsu, Tiffany Y. -T. ;
Desjardins, Michael ;
Baden, Lindsey R. ;
Chan, Brian T. ;
Walker, Bruce D. ;
Lichterfeld, Mathias ;
Brigl, Manfred ;
Kwon, Douglas S. ;
Kanjilal, Sanjat ;
Richardson, Eugene T. ;
Jonsson, A. Helena ;
Alter, Galit ;
Barczak, Amy K. ;
Hanage, William P. ;
Yu, Xu G. ;
Gaiha, Gaurav D. ;
Seaman, Michael S. ;
Cernadas, Manuela ;
Li, Jonathan Z. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2291-2293
[8]   SARS-CoV-2 persistence in immunocompromised children [J].
Dolan, Susan A. ;
Levy, Jean Mulcahy ;
Moss, Angela ;
Pearce, Kelly ;
Butler, Molly ;
Jung, Sarah ;
Dominguez, Samuel R. ;
Mwangi, Eric ;
Maloney, Kelly ;
Rao, Suchitra .
PEDIATRIC BLOOD & CANCER, 2021, 68 (12)
[9]  
European Centre for Disease Prevention and Control, Guidance on ending the isolation period for people with COVID-19
[10]  
Golemba MD, 2022, IN PRESS, DOI [10.1016/j.ram.2022, DOI 10.1016/J.RAM.2022]